Gap 1, or G1, is the first and longest phase of the cell cycle. It’s the period after a cell finishes dividing and before it begins copying its DNA. In a typical human cell with a 24-hour cycle, G1 lasts roughly 11 hours. During this time, the cell grows in size, produces proteins, builds new organelles, and decides whether conditions are right to commit to another round of division.
What Happens During G1
Think of G1 as the cell’s preparation and decision-making window. The cell has just split in two during mitosis, so it’s half its normal size and needs to bulk back up. To do this, it ramps up production of proteins, lipids, and the molecular building blocks it will need later. During early G1, about 50% of active genes enter a hyperactive transcriptional state, creating a burst of activity as the cell gets its machinery running. Synthesis rates for individual proteins shift throughout the phase, with some accumulating faster than others depending on what the cell needs.
A nutrient-sensing system plays a central role in this growth. When amino acids, glucose, and growth factors are all available, a signaling hub called mTORC1 switches on and promotes the production of proteins, fatty acids, cholesterol, and nucleotides. It works like an “AND gate”: both growth factor signals and nutrient signals have to be active at the same time for the green light. If either input is missing, the cell slows or halts its growth program. mTORC1 also suppresses autophagy, the recycling process cells use during starvation, keeping the cell in building mode rather than breakdown mode.
The Restriction Point
The most consequential event in G1 is the restriction point, sometimes just called “R.” This is the moment when a cell commits to dividing and no longer needs external growth factor signals to continue through the cycle. Before R, if you remove growth factors, the cell stops. After R, the cell will proceed to DNA synthesis on its own.
Here’s how the commitment works at a molecular level. Growth factors stimulate the production of a protein called cyclin D, which is unstable and breaks down quickly. Cyclin D pairs with partner enzymes (CDK4 and CDK6) to form active complexes that begin disabling a powerful brake on cell division: the retinoblastoma protein, or Rb. Rb normally sits on top of genes needed for DNA replication, keeping them switched off. As cyclin D-CDK4/6 gradually adds chemical tags (phosphate groups) to Rb, Rb loosens its grip, and those genes start turning on.
This initial wave of Rb inactivation triggers production of cyclin E, which pairs with its own partner enzyme to finish the job, fully disabling Rb. The restriction point sits precisely between these two waves. Once cyclin E is active, it no longer depends on growth factor signaling, which is why the cell becomes self-sufficient at that moment. Cyclin E is the better candidate for the “restriction point protein” because, once expressed, it operates independently of the upstream growth factor pathway.
How Long G1 Lasts in Different Cells
The 11-hour estimate applies to a rapidly dividing human cell in culture, but G1 length varies enormously depending on cell type. Embryonic stem cells have an extremely short G1 phase and divide quickly, with total cycle times around 12 hours. Adult cells are slower. Mouse embryonic fibroblasts, for example, take about 25 hours for a full cycle, with much of that extra time spent in G1.
This variation matters because G1 length is tightly linked to whether a cell stays a stem cell or begins specializing. In somatic (non-stem) cells, a longer G1 phase is associated with differentiation. Artificially lengthening G1 in embryonic stem cells can push them toward becoming specialized cell types. The logic is intuitive: a longer decision window gives the cell more time to respond to signals that direct it away from continued division and toward a particular fate.
When Cells Exit the Cycle: G0
Not every cell that enters G1 moves forward. If conditions aren’t right, a cell can step out of the cycle entirely into a resting state called G0. Several triggers cause this exit: running low on nutrients, losing growth factor signals, bumping up against neighboring cells (contact inhibition), or losing attachment to a surface. Cells can also enter G0 permanently when they reach a fully differentiated state. Neurons and liver cells, for example, spend most of their lives in G0, performing their specialized jobs without dividing.
G0 can also be triggered by DNA damage or the shortening of telomeres (protective caps on chromosome ends) that comes with aging. In these cases, the cell enters a state called senescence, where it’s alive and metabolically active but permanently unable to divide. The distinction between quiescence (reversible G0) and senescence (permanent G0) is important: a quiescent cell can re-enter G1 if conditions improve, while a senescent cell cannot.
Why G1 Control Matters in Cancer
The G1 checkpoint is one of the cell’s primary defenses against uncontrolled growth, and it relies heavily on two tumor suppressor proteins: Rb and p53. Rb, as described above, blocks the genes needed for DNA replication until the cell has properly passed through the restriction point. p53 acts as a damage sensor. If DNA is damaged, p53 can halt the cell in G1, trigger repair, or, if the damage is too severe, push the cell toward self-destruction.
Together, these two proteins enforce cell cycle arrest, senescence, and programmed cell death. When both are genetically inactivated, which is common in advanced cancers, the cell permanently loses these protective mechanisms. It can blow through G1 without adequate growth signals, ignore DNA damage, and resist therapies designed to reactivate these checkpoints. The inactivation of both Rb and p53 pathways helps explain why more advanced cancers are harder to treat: the two most fundamental braking systems are gone.
Many cancer-driving mutations cluster in the G1 control pathway. Overproduction of cyclin D, loss of proteins that inhibit CDK4/6, or direct mutation of Rb all have the same functional result: the restriction point no longer works as a gate. This is why a class of cancer drugs targeting CDK4 and CDK6 has become a mainstay in treating certain breast cancers. These drugs essentially try to re-impose the G1 brake that the tumor has learned to bypass.